Trial · NCT07903428
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Enrolment | 12 months | (i) Average enrolment of 1 patient/centre/2 months |
| Primary | Consent rate | 12 months | (ii) We will target a consent rate of \> 90%. |
| Primary | Protocol adherence | 12 months | (iii) We will target \> 96% protocol adherence defined by successful predictive model and DA report generation, for both the preWLSM and postWLSM reports, with red light upper cutoffs of 70%. |
| Primary | DA report delivery (a) | 12 months | (iv) a) We will target \>96% confirmed delivery of DA report to at least one transplant physician and donation physician to assist clinical decision-making in the intervention arm, for both the preWLSM and postWLSM reports, with red light upper cutoffs of 70%. |
| Primary | DA report delivery (b) | 12 months | (iv) b) We will target \>85% successful generation and delivery (to at least one transplant physician and donation physician) of both reports, with a red-light upper cutoff of 58%. Of the primary outcome measurements, this applies only to the intervention arm. |
| Primary | Outcome Data Collection (a) | 18 months | (a) proportion of patients consented for DCC that proceed to DCC attempt |
| Primary | Outcome Data Collection (b) | 18 months | (b) proportion of successful and unsuccessful DCC attempts |
| Primary | Outcome Data Collection (c) | 18 months | (c) time to death of all patients consented for DCC |
| Primary | Outcome Data Collection (d) | 18 months | (d) organs retrieved |
| Primary | Outcome Data Collection (e) | 18 months | (e) organs transplanted |
| Primary | Outcome Data Collection (f) | 18 months | (f) organs functional at 90 days |
| Secondary | Identify stakeholder barriers and drivers for DA implementation (qualitative outcome) | 18 months | The secondary objective of the study is to identify stakeholder barriers and drivers for DA implementation. This will be done by assessing experiences and opinions from four clinician teams exposed to DA, identifying barriers, drivers, and utility perceptions through interviews based on the TFA and GUIDES checklist. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07903428/registered